Skip to content
Dose Brief
Menu
No. 6 on the board · Grade B+Editorial review

Ro review

A heavyweight platform with brand-name access and a polished experience — but it keeps compounded pricing off the record.

Visit Ro Editorial review — no commercial relationship.
Semaglutide
Not disclosed
Tirzepatide
Not disclosed
Coverage
Multi-state
Brand-name
Yes
On the trackerStableprice stableBrand-name access and insurance navigation, but compounded pricing stays off the record.

The scorecard

Ro scored on our six Brief Score factors. See the methodology.

Price Stability80/100
Supply Reliability90/100
Transparency80/100
Access Breadth92/100
Clinical Oversight90/100
Track Record89/100

What we like

  • Brand-name (Wegovy/Zepbound) access and insurance support
  • Oral options
  • Well-funded, reliable platform

The caveats

  • Does not publicly disclose compounded pricing up front
  • Premium positioning

The brief

Best for: Readers who want a big, brand-name-capable platform and insurance navigation over a published flat price. A heavyweight platform with brand-name access and a polished experience — but it keeps compounded pricing off the record.

Ranked #6 of 9 providers we reviewed — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 8 other providers we've reviewed, in our overall ranking order.

Pricing, states and verification reflect Ro's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on Ro's site. Not medical advice; see our disclosure.

← Back to all rankings